Published: January 2013
|Formats||Member Price||Nonmember Price|
|Individual Download||$99 / €90||$410 / €355|
|Which format is right for me?|
Recent survey results show that the pharmaceutical companies often take an overly conservative approach to NIMPs (or Non-IMPs) due to regulatory and operational ambiguity. This can lead to unnecessary expenses and process steps, which can needlessly complicate clinical trials.
The ISPE Good Practice Guide: Harmonizing the Definition and Use of Non-Investigational Medicinal Products (NIMPs) aims to provide practical operational guidance and drive a consistent industry approach to the use of NIMPs. The Guide contains criteria for classifying NIMPs and an overview of current NIMP regulatory requirements.
This in-depth Guide will help you properly manage NIMPs by providing guidance on:
Are You Ready for an FDA Audit of Your Downstream Process?
Thursday, 27 Apr 2017 08.04
Meet PT Kalbio Global Medika – 2017 FOYA Honorable Mention Winner
Wednesday, 26 Apr 2017 09.04
Maximize Your Professional Development at These Signature Events
Tuesday, 25 Apr 2017 12.04